Comanagement News

CHICAGO – Patients with Sjögren’s syndrome were found to have significantly worse ocular surface and Delphi global staining scores than patients with aqueous deficient dry eye, according to a study presented at the American Academy of Optometry meeting.

QPI-1007 is being investigated for providing neuroprotection against nonarteritic anterior ischemic optic neuropathy, which has no standard treatment and is a leading cause of sudden optic nerve-related vision loss in individuals older than 50 years.

In spite of the constant media blitz related to health, health care policy, the health care laws and health care reform, little has changed in the day-to-day delivery of health care services.

Google “will stents replace bypass surgery?” and within 0.53 seconds you’ll have more than 450,000 results. This is pretty amazing when you consider it’s been more than 30 years since Sigwart and colleagues deployed the first coronary artery stent as a scaffold during transluminal angioplasty in an attempt to prevent restenosis.

Micro-invasive glaucoma surgery is providing long-term IOP control for patients with mild to moderate glaucoma and allowing clinicians to intervene earlier in the glaucoma lifecycle

The CDC’s National Diabetes Statistics Report 2017 shows that half of Americans have diabetes or are at risk for it. Specifically, this sight-threatening condition affects more than 30.3 million, or one in 10 Americans, with about 7.2 million adults unaware they have it or undiagnosed and another 84.1 million adults pre-diabetic, according to the report.

A recent and exciting FDA approval for the RxSight Light Adjustable Lens and Light Delivery Device has been achieved.

There’s no question that MIGS has become a worthwhile add-on to cataract surgery. The well-deserved amount of attention in journals and at meetings to these new procedures is impressive. Still, it’s surprising that only about 16% of U.S. surgeons are using these devices and techniques, per several industry sources.

Erin Kenny, OD, outlines her talk on retinal implants at the New Jersey Academy of Optometry fall dinner meeting. She said Argus II (Second Sight) is the only FDA-approved retinal implant in the U.S. and mentions a successful case study.

Surgery with the Trabectome significantly reduces IOP in patients with glaucoma and has the highest rate of success when baseline IOP is lower, the cornea is thinner and cataract surgery is performed at the same time, according to a study.